Stroke in Atrial Fibrillation - Long-term Follow-up of Cardiovascular Events
Related Experiment Video
Updated: Mar 26, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Tze-Fan Chao1, Chern-En Chiang2, Shih-Ann Chen1
1Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital; Institute of Clinical Medicine and Cardiovascular Research Center, National Yang-Ming University.
Insights
Atrial fibrillation (AF) stroke risk is significant, but the CHA2DS2-VASc score helps identify low-risk patients. New biomarkers and imaging may refine stroke prevention strategies for AF patients.
Area of Science:
- Cardiology
- Neurology
- Public Health
Background:
- Atrial fibrillation (AF) affects 1.5 per 1000 person-years in Taiwan.
- Systemic thromboembolism is a severe AF complication.
- Risk stratification and prophylaxis are key in AF management.
Purpose of the Study:
- To evaluate the utility of the CHA2DS2-VASc score in AF patients.
- To explore the role of novel biomarkers and imaging in predicting adverse events.
- To assess potential changes in stroke prevention strategies for AF.
Main Methods:
- Utilizing the CHA2DS2-VASc score for risk stratification.
- Reviewing recent literature on biomarkers and imaging parameters in AF.
- Analyzing their association with thromboembolic events and mortality.
Main Results:
- The CHA2DS2-VASc score effectively identifies low-risk AF patients.
- Biomarkers and imaging parameters show associations with adverse outcomes.
- Current risk stratification may be enhanced by these new tools.
Conclusions:
- The CHA2DS2-VASc score is crucial for guiding anticoagulation in AF.
- Emerging biomarkers and imaging hold promise for improving stroke risk prediction.
- Further research is needed to integrate these findings into clinical practice for AF stroke prevention.
Abstract:
The incidence of atrial fibrillation (AF) was around 1.5 per 1000 person-years in Taiwan. Systemic thromboembolism is the most severe complication of AF. Risk stratification and adequate thromboembolism prophylaxis is the cornerstone of treatment in AF patients. The CHA2DS2-VASc score is powerful in selecting "truly low-risk" patients who are not necessary to receive anticoagulation therapies. It is also useful in predicting thromboembolic events and mortality for patients undergoing AF ablation. Recently, more and more biomarkers and imaging parameters were reported to be associated with adverse events in AF patients. How could these biomarkers and imaging tools change the current strategy of stroke prevention in AF deserves further investigations.
More Related Videos
28:13Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
08:10Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Endocarditis III: Medical Management
Atherosclerosis III: Management
Myocarditis IV: Nursing Management
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis IV: Nursing Management